Table 3:
Changes in systolic blood pressure and LDL cholesterol, in pre-specified subgroups
| End Point | Subgroup | Polypill | Usual Care | |||
|---|---|---|---|---|---|---|
| Baseline | 12 mos | Baseline | 12 mos | Interaction P | ||
| SBP, mmHg | Male (n=103) | 144 (20) | 136 (23) | 140 (16) | 135 (20) | 0.15 |
| Female (n=172) | 138 (17) | 128 (19) | 140 (18) | 139 (25) | ||
| Stage 2 HTN (n=119) | 157 (16) | 141 (21) | 156 (14) | 151 (25) | 0.21 | |
| No stage 2 HTN (n=156) | 127 (6) | 123 (16) | 128 (6) | 129 (17) | ||
| On baseline therapy (n=146) | 139 (17) | 131 (19) | 142 (18) | 142 (25) | 0.82 | |
| No baseline therapy (n=129) | 142 (20) | 132 (22) | 137 (16) | 133 (20) | ||
| LDL cholesterol, mg/dl | Male (n=102) | 105 (36) | 93 (35) | 101 (38) | 100 (34) | 0.84 |
| Female (n=171) | 118 (30) | 101 (35) | 119 (35) | 114 (29) | ||
| LDL ≥ 130 (n=81) | 151 (17) | 122 (33) | 157 (19) | 137 (26) | 0.55 | |
| LDL < 130 (n=192) | 98 (23) | 88 (30) | 94 (24) | 97 (26) | ||
| On baseline statin (n=43) | 108 (33) | 101 (31) | 102 (30) | 102 (25) | 0.53 | |
| No baseline statin (n=230) | 114 (33) | 98 (35) | 115 (38) | 110 (33) | ||
Values shown are mean (SD). SBP, systolic blood pressure; HTN, hypertension. Twenty participants in the polypill arm and 8 participants in the usual care arm discontinued trial participation and did not have data at 12 months. In addition, two participants in the polypill arm had missing LDL cholesterol data, due to insufficient blood sample (n=1) or missing baseline direct LDL cholesterol measurement (n=1). For SBP, ‘baseline therapy’ refers to ongoing pre-enrollment use of any prescription anti-hypertensive therapy.